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A prospective study was undertaken to assess the type and frequency of adverse side-effects following the use of intravenous
phenytoin in children. Twenty-two children received a total of 100 doses over a 10-month period. Six patients (27%) experienced
one or more side-effects, including extravasation of the drug, hypotension and cardiac arrhythmia. No patient developed skin
necrosis, including the ‘purple glove syndrome’. Recovery from all adverse side-effects was spontaneous and complete. It is
possible that some or all of these side-effects may have been caused by an excessive rate of infusion of phenytoin or the saline
‘flush’ following administration of the drug. The overall frequency of side-effects was perhaps less than expected.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Phenytoin has been used in the management of
epilepsy for over half a century. Together with intra-
venous (i.v.) phenobarbitone, i.v. phenytoin remains
one of the preferred long-acting anti-convulsant
drugs in treating convulsive (tonic–clonic) status
epilepticus1. The primary advantage of phenytoin
compared to phenobarbitone is that it is not asso-
ciated with any significant sedation or respiratory
difficulties. However, i.v. phenytoin may induce hy-
potension and cardiac arrhythmias if infused too
quickly and may also cause tissue necrosis, including
the ‘purple glove syndrome’ (PGS)2–7, if extrava-
sation occurs at the site of i.v. cannulation. Despite
these potentially serious adverse events, it is some-
what surprising that they have been the subject of
relatively few published reports. It is possible that
this may simply reflect an under-reporting of these
side-effects8, 9.
Fosphenytoin is a recently introduced pro-drug of
phenytoin, which being water soluble rather than lipid
soluble (as is phenytoin) may be administered more
rapidly and it is also reported to be associated with a
far lower risk of causing tissue necrosis and pain when
there is extravasation of the drug10, 11. However, there
are very few paediatric data12 on this reportedly lower
complication rate of fosphenytoin and, importantly,
the current cost of fosphenytoin is at least fivefold
greater than that of phenytoin.
The objective of this survey was to prospectively de-
scribe the incidence of adverse side-effects associated
with the use of i.v. phenytoin in an attempt to evaluate
the frequency and extent of the risks of its use and,
consequently, to potentially support the justification
for replacing this drug with fosphenytoin.
PATIENTS AND METHODS
Data collection forms were designed, piloted and sub-
sequently distributed to all clinical areas in the hospi-
tal where i.v. phenytoin was being used. These areas
included all the medical and surgical wards, the Acci-
dent & Emergency (A & E department) and the paedi-
atric intensive care unit (PICU) in a large Children’s
Teaching Hospital. Nursing and medical staff in the
clinical areas were instructed on the purpose of this
study and how to record the data on the study forms
and subsequently asked to complete a data collection
form for every dose of i.v. phenytoin administered over
the study period.
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Demographic data were collected on the following:
the patient’s age and sex; dose of phenytoin; rate of
phenytoin infusion and rate of ‘flush’ following the
administration of phenytoin and possible/probable ad-
verse events following each dose. The specific adverse
events that were recorded included the following: ery-
thema at the site of an injection, pain at the site of the
injection, incidence of the ‘PGS’, whether the i.v. can-
nula required re-siting, whether the prescribed dose
of phenytoin had to be administered again because
of prematurely terminating the infusion because of
any local or systemic adverse event, and whether the
patient developed hypotension or any cardiac arrhyth-
mia (as identified on continuous electrocardiographic
monitoring) during the infusions. Information was
not collected on the weight and height of the patient,
the clinical indication for administering phenytoin
and blood levels of phenytoin.
RESULTS
Twenty-two patients (12 male) were administered 100
separate doses of i.v. phenytoin during the 10-month
study period. Phenytoin was administered in seven
clinical areas including the A & E department, the
PICU, four medical wards and the neonatal surgical
unit. The patients ages ranged from 0.5 to 14.2 years
with a median age of 5.2 years. Sixty-one doses of
phenytoin were administered in the PICU, 38 in the
four medical and one surgical wards, and one in the
A & E department.
In 88 exposures, the i.v. cannula was placed in the
upper limb (antecubital fossa or dorsum of the hand);
in 12 the cannula was inserted in the lower limb (dor-
sum of foot or femoral vein within the groin). The
size of the peripheral i.v. cannula or butterfly needle
was 20–22 gauge in all 39 non-PICU doses. Approxi-
mately, 75% of the doses administered in PICU were
through a central venous line but the precise gauge of
needle used in the remaining 25% of the peripheral
venous cannulations was not recorded.
Saline (0.9%) ‘flushes’ following the infusion of
phenytoin were used in all 100 doses.
Six patients (27%) experienced an adverse event
that was considered to be directly related to the in-
fusion of i.v. phenytoin, including extravasation and
cutaneous infiltration (three patients), occlusion of the
peripheral i.v. line (two patients), hypotension (one
patient) and cardiac arrhythmia (tachycardia, (one
patient)). One patient experienced two adverse events
(drug extravasation and peripheral vein occlusion).
The episodes of hypotension and cardiac arrhythmia
resolved spontaneously within 30 minutes of discon-
tinuing the infusion of phenytoin. Seven of the 100
doses exceeded the minimum recommended infusion
rate of 20 minutes. Forty-eight doses were ‘flushed’
more rapidly than the recommended infusion rate of
20–30 minutes (the recommendations are based on
the drug’s data sheet and local pharmacy guidelines).
These excessive rates of infusion (of either the pheny-
toin or the subsequent, saline ‘flush’) could potentially
have explained the two episodes of hypotension and
cardiac arrhythmia. No patient developed either the
‘PGS’ or demonstrated any significant skin discol-
oration or ulceration at the site of the i.v. cannulation,
including the four patients who experienced extrava-
sation of the drug and/or occlusion of the peripheral
venous line. Two patients complained of transient dis-
comfort and pruritis at the cannulation site (both can-
nulae sited in the dorsum of the hand), which did not
necessitate discontinuing the phenytoin infusion and
which resolved on completion of the phenytoin infu-
sion. The two patients who developed peripheral vein
occlusion required insertion of replacement i.v. can-
nulae and one of these two patients also had the dose
of phenytoin repeated. No additional interventions or
replacement cannulae or repeat drug infusions were
required in the remaining 20 patients or 98 doses. The
patient who developed the cardiac arrhythmia was
resident on the PICU; the other five patients were on
one of the medical wards. One of these patients was
a 15-year-old boy with severe learning and behaviour
difficulties who experienced both extravasation of
phenytoin and occlusion of a peripheral cannula, com-
plications that were felt to possibly reflect his impaired
understanding and co-operation with procedures.
The doses of i.v. phenytoin were between 18 and
20 mg/kg/dose for all loading doses and between 3
and 6 mg/kg/dose for all maintenance doses; all main-
tenance doses were given on the basis of a twice daily
dosing regime. All adverse events occurred in patients
receiving maintenance doses of phenytoin.
DISCUSSION
This study has demonstrated that the use of i.v. pheny-
toin in children may be associated with potentially se-
rious side-effects, with over one quarter of the patients
reporting at least one adverse event. Four patients ex-
perienced a local complication with either occlusion
of a peripheral vein or extravasation into the skin but
without any local erythema, ulceration or development
of ‘PGS’. Two other patients experienced a systemic
complication that was considered to be related to an
excessive rate of infusion of either phenytoin or the
subsequent saline ‘flush’. All local and systemic com-
plications were transient and other than requiring the
insertion of new i.v. cannulae in two patients, resolved
spontaneously. The patients otherwise required no ad-
ditional interventions or procedures (and, therefore, no
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additional expense) as a direct consequence of these
adverse events. Only one patient required a repeat dose
of phenytoin, following occlusion of the peripheral
cannula.
As far as we are aware, all phenytoin doses were
‘captured’ and, therefore, surveyed during the study
period, by cross-checking ward supplies and pharmacy
records. However, it is possible that some doses may
have been missed, although these are likely to repre-
sent a very small number.
The local and systemic complications of i.v. pheny-
toin have been recognised for many years2. The
specific local complication of the ‘PGS’ (oedema,
discoloration and pain, distal to the site of the i.v. ad-
ministration of the drug) has been the focus of most
previous reports2–7, including a recent prospective
study7. In this study of 157 adult patients (receiving
a total of 179 doses), two patients (three doses; 1.7%)
developed ‘PGS’ but there was no report of other,
less serious local complications and no comment on
any systemic, cardiovascular adverse events7.
Although phenytoin is a weak organic acid, its vehi-
cle or carrier is highly alkaline (pH 12) and is poorly
soluble at a neutral pH. Ethanol and propylene gly-
col are added to phenytoin and its carrier (sodium
hydroxide) to enhance its solubility and these com-
pounds are highly irritating to soft tissue and may re-
sult in tissue necrosis if there is extravasation of the
drug1. Fosphenytoin is a pro-drug of phenytoin that
is both water soluble and uses a vehicle that is less
toxic than phenytoin (pH 8.6–9)10. As a result it is
considered to be associated with fewer local complica-
tions, including specifically, the ‘PGS’. An additional
reported benefit of i.v. fosphenytoin is its safer cardio-
vascular profile with a far lower risk of inducing hy-
potension and cardiac arrhythmias10, 12, 13. However,
this early optimism may have been somewhat prema-
ture following a report by the Committee on Safety of
Medicines (CSM) in the UK of serious arrhythmias
and hypotension following the infusion of fospheny-
toin at the ‘recommended’ infusion rates14. There are
two additional disadvantages of using i.v. fospheny-
toin, one of which is potential and the other real. The
potential disadvantage is that because the dosing of
this drug is in ‘phenytoin equivalents’ this may result
in potential confusion and prescribing errors, result-
ing specifically in administering higher than intended
doses. The other, and real disadvantage is that as of late
2002, for equivalent dosing, i.v. fosphenytoin costs at
least five times that of phenytoin.
A number of reports have been published that have
attempted to justify the increased cost of using fos-
phenytoin on the basis of the potential complication
rate and frequency of adverse events with phenytoin
and specifically the costs incurred in treating these ad-
verse events8, 15, 16. These costs may potentially range
from replacing a single i.v. cannula, the use of dress-
ings and antibiotics to treat any local skin ulceration
and secondary infection, the funding of acute resus-
citation and treatment (including intensive care) for
treating hypotension and cardiac arrhythmias, the use
of plastic surgery in treating the ‘PGS’ to expensive
legal costs arising from either the excessive dosing of
phenytoin or an inappropriate rate of infusion. Clearly,
many if not most of these costs are hypothetical rather
than actual and generally, this pharmaco-economic ar-
gument is somewhat artificial. One could reasonably
argue that because the local and systemic side-effects
of i.v. phenytoin are well recognised, as are the guide-
lines and recommendations as to how the drug should
be administered, there should, therefore, be a low
risk (and incidence) of serious adverse events. The
results of the present study would lend some support
to this argument. In addition, one could reasonably
have expected that the frequency of local adverse
events (including specifically the ‘PGS’) would have
been greater because of the smaller diameter of
children’s veins and the difficulties in cannulating
these veins.
Although the numbers in this prospective study are
relatively small, it is unlikely that the results could
be used to support or justify the replacement of i.v.
phenytoin with i.v. fosphenytoin in routine paediatric
practice.
Finally, in the United States, the branded or pro-
prietary form of i.v. phenytoin (Dilantin®), has now
been withdrawn by Parke-Davis and replaced with its
branded formulation of fosphenytoin, (Cerebyx®) At
the time of writing, Parke-Davis is not planning to
withdraw its UK proprietary formulation of phenytoin,
(Epanutin® Ready-mixed Parenteral; personal com-
munication).
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